Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (3190)	6/15/2018 4:19:21 PM
From: Miljenko Zuanic	Respond to of 3202

bloodjournal.org < In an age- and sex-matched control group with none or conventional therapy (N=44), 7 patients (15.9%) tested positive for IgR (Figure 1E). This indicates the presence of clonal B-cells in the bone marrow of approximately 15% of PMF patients regardless of treatment.> So, IF statics hold (for JAK1/2 involvement in progression to cancer), 1/3 of those clone identified may develop aB-cL on treatment? That is bad! RE: REGN This is somehow positive for REGN, because all those a-topic allergic conditions that may be targeted with selective JAK1 may be "At risk" for B-CL!